Based on preclinical studies and observations made in HCC tumors, the targeting of other NK cell inhibitory receptors such as TIGIT [264], Siglec-7 [265] or LAG3 [266,267], represents suitable therapeutic options that warrant further investigation. Here, TIGIT is linked to hepatocellular carcinoma.